7 research outputs found

    Bartonella Endocarditis Presenting as Recurrent Cerebral Mycotic Aneurysm.

    No full text
    Bartonella henselae is a known cause of culture-negative endocarditis, which can be difficult to diagnose without a high clinical suspicion as specific diagnostic testing is required. We report the case of a 48-year-old male who presented with altered sensorium. A CT of the head showed left-hemispheric intracranial hemorrhage (ICH) likely secondary to ruptured left posterior cerebral artery (PCA) fusiform aneurysm seen on catheter cerebral angiogram, which was treated with endovascular embolization. The patient had a significant history of mitral valve prolapse; however, a transthoracic echocardiogram (TTE) was negative for any vegetation. Blood cultures were also negative. A year later, he presented with another ICH in the PCA territory and was found to have a new left distal PCA aneurysm, which was again treated with endovascular embolization. During that hospitalization, an echocardiogram showed myxomatous changes in the mitral valve with severe mitral regurgitation; however, blood cultures were negative. Further queries about the patient\u27s social history revealed that his spouse had been a cat owner in 2018, which prompted Bartonella henselae testing. The blood work showed elevated immunoglobulin G (IgG) titers for which he was placed on antibiotics. A follow-up catheter angiogram detected a new distal middle cerebral artery (MCA) M4 branch aneurysm treated with surgical clipping. The aneurysm tested positive for Bartonella henselae on polymerase chain reaction (PCR) testing. The patient subsequently underwent successful mitral valve replacement, which also was positive for Bartonella henselae on PCR testing; however, the Warthin-Starry stain was negative. This case demonstrates how a comprehensive history along with persistent evaluation for the underlying etiology of cerebral aneurysms can lead to the diagnosis of Bartonella henselae endocarditis. Cerebral mycotic aneurysms are known complications of endocarditis; however, the underlying infection can be difficult to diagnose. Recognition of this culture-negative endocarditis is critical for the appropriate treatment and management of patients to prevent morbidity and mortality

    Abstract Number ‐ 155: CT Perfusion May Optimize Selection Of Elderly Patients For Mechanical Stroke Thrombectomy

    No full text
    Introduction Prior studies have demonstrated that CT perfusion (CTP) may be used to select patients for mechanical stroke thrombectomy (MST) with acute ischemic stroke owing to major artery obstruction in the anterior circulation for up to 24 hours. There is limited data on CTP selection of elderly patients aged ≥ 90 years old. We aimed to examine whether selecting nonagenarians with CT perfusion (CTP) imaging would allow for better outcomes. Specifically we aimed to examine hypoperfusion intensity ratio (HIR) and early infarct growth rate (EIGR) to optimize MST selection of nonagenarians. Methods This is a single center retrospective study from a large academic medical center. Patients included were at least 90 years old, presented with an anterior circulation acute ischemic stroke due to large vessel occlusion (LVO) and were treated with mechanical stroke thrombectomy (MST) between January 2018 and April 2022. Patients without CT perfusion (CTP) imaging prior to MST and without complete data were excluded. HIR was defined as time to maximum (Tmax 10 seconds/ Tmax 6 seconds). EIGR was defined as (relative cerebral blood flow 2) at 90 days. HIR was found to be correlated with 90 day mRS (shift to next worse mRS), adjusted odds ratio (aOR) = 14.41 [95%CI 1.16, 179.11] p = 0.04, but not EIGR, aOR = 0.98 [95%CI 0.90, 1.06], p = 0.58. Neither HIR nor EIGR were not associated with excellent reperfusion, p = 0.38 and p = 0.88, respectively. Patients with higher EIGR were more likely to experience proceduralcomplications, aOR = 1.16 [95%CI 1.03, 1.31], p = 0.01, but there was no difference in HIR, p = 0.28. Lastly, there were no differences in HIR or EIGR and sICH, p = 0.07 and p = 0.68, respectively. Conclusions Very elderly patients aged 90 years or older experienced high rates of mortality and low proportions of good outcomes at 90 days. Nonagenarians with better collaterals as measured by HIR may have better outcomes at 90 days. Additionally, nonagenarians with faster growing ischemic cores may be more likely to experience complications during MST

    Predictors of Functional and Quality of Life Outcomes following Deep Brain Stimulation Surgery in Parkinson’s Disease Patients: Disease, Patient, and Surgical Factors

    No full text
    Objective. The primary objective was to evaluate predictors of quality of life (QOL) and functional outcomes following deep brain stimulation (DBS) in Parkinson’s disease (PD) patients. The secondary objective was to identify predictors of global improvement. Methods. PD patients who underwent DBS at our Center from 2006 to 2011 were evaluated by chart review and email/phone survey. Postoperative UPDRS II and EQ-5D were analyzed using simple linear regression adjusting for preoperative score. For global outcomes, we utilized the Patient Global Impression of Change Scale (PGIS) and the Clinician Global Impression of Change Scale (CGIS). Results. There were 130 patients in the dataset. Preoperative and postoperative UPDRS II and EQ-5D were available for 45 patients, PGIS for 67 patients, and CGIS for 116 patients. Patients with falls/postural instability had 6-month functional scores and 1-year QOL scores that were significantly worse than patients without falls/postural instability. For every 1-point increase in preoperative UPDRS III and for every 1-unit increase in body mass index (BMI), the 6-month functional scores significantly worsened. Patients with tremors, without dyskinesia, and without gait-freezing were more likely to have “much” or “very much” improved CGIS. Conclusions. Presence of postural instability, high BMI, and worse baseline motor scores were the greatest predictors of poorer functional and QOL outcomes after DBS

    Pivotal Trial of the Neuroform Atlas Stent for Treatment of Anterior Circulation Aneurysms

    No full text
    Background and purposeStent-assisted coil embolization using the new generation Neuroform Atlas Stent System has shown promising safety and efficacy. The primary study results of the anterior circulation aneurysm cohort of the treatment of wide-neck, saccular, intracranial, aneurysms with the Neuroform Atlas Stent System (ATLAS trial [Safety and Effectiveness of the Treatment of Wide Neck, Saccular Intracranial Aneurysms With the Neuroform Atlas Stent System]) are presented.MethodsATLAS IDE trial (Investigational Device Exemption) is a prospective, multicenter, single-arm, open-label study of wide-neck (neck ≥4 mm or dome-to-neck ratio <2) intracranial aneurysms in the anterior circulation treated with the Neuroform Atlas Stent and approved coils. The primary efficacy end point was complete aneurysm occlusion (Raymond-Roy class 1) on 12-month angiography, in the absence of retreatment or parent artery stenosis (>50%) at the target location. The primary safety end point was any major stroke or ipsilateral stroke or neurological death within 12 months. Adjudication of the primary end points was performed by an independent Imaging Core Laboratory and the Clinical Events Committee.ResultsA total of 182 patients with wide-neck anterior circulation aneurysms at 25 US centers were enrolled. The mean age was 60.3±11.4 years, 73.1% (133/182) women, and 80.8% (147/182) white. Mean aneurysm size was 6.1±2.2 mm, mean neck width was 4.1±1.2 mm, and mean dome-to-neck ratio was 1.2±0.3. The most frequent aneurysm locations were the anterior communicating artery (64/182, 35.2%), internal carotid artery ophthalmic artery segment (29/182, 15.9%), and middle cerebral artery bifurcation (27/182, 14.8%). Stents were placed in the anticipated anatomic location in all patients. The study met both primary safety and efficacy end points. The composite primary efficacy end point of complete aneurysm occlusion (Raymond-Roy 1) without parent artery stenosis or aneurysm retreatment was achieved in 84.7% (95% CI, 78.6%-90.9%) of patients. Overall, 4.4% (8/182, 95% CI, 1.9%-8.5%) of patients experienced a primary safety end point of major ipsilateral stroke or neurological death.ConclusionsIn the ATLAS IDE anterior circulation aneurysm cohort premarket approval study, the Neuroform Atlas stent with adjunctive coiling met the primary end points and demonstrated high rates of long-term complete aneurysm occlusion at 12 months, with 100% technical success and <5% morbidity. Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02340585

    ESICM LIVES 2016: part two : Milan, Italy. 1-5 October 2016.

    Get PDF
    Meeting abstrac
    corecore